Currently available treatment with proven outcomes Semaglutide FDA-approved for diabetes (Ozempic), obesity (Wegovy), and CV risk reduction with 7+ years of clinical and post-marketing data Cardiovascular risk reduction Semaglutide SELECT trial demonstrated 20% MACE reduction in 17,604 patients -- the first anti-obesity drug with proven cardiovascular benefit Maximum weight loss potential Retatrutide Phase 2 data showed 24.2% weight loss at 48 weeks with weight curves still declining, though Phase 3 confirmation is required Metabolic liver disease (MASLD/MASH) Retatrutide Glucagon receptor agonism directly promotes hepatic fat oxidation, a mechanistic advantage for liver-specific outcomes Oral administration preference Semaglutide Only incretin-class drug available as an oral tablet (Rybelsus), with higher-dose oral formulations under development Type 2 diabetes with established treatment guidelines Semaglutide Integrated into clinical guidelines with multiple approved doses and formulations, extensive comparative data, and guideline positioning Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly
Properly preparing Retatrutide for research use is a critical step in maintaining the peptides stability, accuracy, and potency
Strategies for managing this period include maintaining close communication with your healthcare provider about side effects, using all available anti-nausea strategies proactively rather than reactively, accepting that some temporary discomfort accompanies effective treatment, focusing on the progress already made rather than the challenges remaining, and remembering that 85% of patients report minimal side effects by month four
CagriSema: A Dual-Target Therapy for Obesity and Type 2 Diabetes Novo Nordisk unveiled the Phase 3 results from the REDEFINE 1 and REDEFINE 2 studies of CagriSema, a fixed-dose combination of cagrilintide (an amylin analog) and semaglutide
